ATP-dependent FK866 inhibition constants for human NAMPT
Biochemical assay · Purified recombinant human NAMPT; cell-free NMN synthesis assay [1]
FK866 inhibited human NAMPT in both ATP-coupled and non-ATP-coupled assays. The reported constants depended on ATP coupling and the substrate used for the kinetic analysis; they are Ki values rather than cellular IC50 values.
| Endpoint | Reported result | Reference |
|---|---|---|
| Non-ATP-coupled NMN synthesis, with respect to PRPP | Ki 730 ± 75 pM | [1] |
| Non-ATP-coupled NMN synthesis, with respect to NAM | Ki 5000 ± 500 pM | [1] |
| ATP-coupled NMN synthesis, with respect to PRPP | Ki 10 ± 1 pM | [1] |
| ATP-coupled NMN synthesis, with respect to NAM | Ki 150 ± 18 pM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Inhibitor concentrations varied to cover 0–80% inhibition; exact FK866 concentration series not specified in the adopted method text.
- Exposure duration
- Three samples quenched at 15-minute intervals for initial-rate measurements.
- Method
- 25°C, pH 7.5. ATP-coupled method: 200 μM PRPP, 100 nM radiolabeled NAM, 2.5 mM ATP, 5 mM MgCl2 and 2.2 nM enzyme in 50 mM HEPES, 50 mM NaCl and 1 mM THP. Without ATP: 100 μM PRPP, 1 μM radiolabeled NAM and 88 nM enzyme with the stated buffer components.
- Co-treatment
- ATP-present and ATP-absent assay conditions; other inhibitors in Table 2 are comparators, not co-treatments.
- Reported limits
- FK866 supplier, stock vehicle and explicit salt form not identified in read material text. Reported ± is not assigned SD or SEM.
Methods and source locations
Compound reported in the paper: FK866; Compound label in the paper: FK866
Compound-level research findings; no validation of A11279 purity, lot, salt equivalence or performance.
Table 2, FK866 row, PRPP/NAM columns with and without ATP; Experimental Procedures: NAMPT Inhibition and Analysis of Data; Results: Inhibition Studies
Non-ATP-coupled NMN synthesis, with respect to PRPP: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; Non-ATP-coupled NMN synthesis, with respect to PRPP
Non-ATP-coupled NMN synthesis, with respect to NAM: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; Non-ATP-coupled NMN synthesis, with respect to NAM
ATP-coupled NMN synthesis, with respect to PRPP: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; ATP-coupled NMN synthesis, with respect to PRPP
ATP-coupled NMN synthesis, with respect to NAM: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; ATP-coupled NMN synthesis, with respect to NAM